Intrapleural Minocyclin Instilla Intrapleural Minocyclin Instillation Vs Bleomycin in Management of Recurrent Pleural effusion Mohammed J Jameel* FIBMS
Background: Chemical pleurodesis was described to manage malignant pleural effusion, it is effective and associate with least morbidity and can be carried out as an outpatient procedure.
Objectives: To discuss uses of minocyclin as seclerosant agent to induce chemical pleurodesis in comparison to bleomycin from other studies regarding success rate, cost, side effects and acceptability.
Methods: A prospective study is carried out from February 2014 till April 2017 on 45 patients presented with recurrent pleural effusion, malignant in 29 patients (64.4%) and non malignant in 16 patients (35.6%) on an outpatient base.
Results: After 2-9 months follow up period (mean ±SD is 5 ±1.2). Intrapleural minocyclin instillation was successful in 39 patients (86.7%) as all over (successful result was reported when there was no recurrence of effusion within 30 days post instillation), no mortality reported. Reported side effects of minocyclin like chest pain in seven patients (15.5%), nausea and vomiting in five patients (11%), elevated serum bilirubin in two patients (4.4%). Recurrent effusion in six patients (13.3%).
Conclusion: Chemical pleurodesis using minocyclin instillation is safe and effective and can be carried out as an outpatient procedure. Minocyclin is one of the best materials available regarding lower side effect in comparison to bleomycin, cheap and acceptable by patients.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share — copy and redistribute the material in any medium or format
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.